Kennedy, Jr. doubled down on his support for non-pharmaceutical health treatments during a recent podcast appearance, saying, ...

After 25 years, a pair of doctors at Memorial Sloan Kettering studying stem-cell therapy are optimistic. Former Biden press ...

This first-in-human trial is testing a highly unconventional method: delivering fat-derived stem cells from the patient ...

Only a handful of stem cell therapies are currently approved by the F.D.A., mainly for treating blood cancer and immune ...

Data show SPR301 lowered α-synuclein, a hallmark of Parkinson’s disease, in cellular models, indicating potential for efficacy at doses with favorable safety Demonstrated greater α-synuclein ...

An estimated 8,000 people in Singapore live with the disease. Read more at straitstimes.com. Read more at straitstimes.com.

Discover how Bayer and BlueRock are redefining biotech partnerships. From breakthrough Parkinson’s therapies to a unique “arm ...

Despite a National Deep Brain Stimulation Service in operation since 2022, insufficient resources mean that many Irish ...

Bayer subsidiary BlueRock Therapeutics has dosed the first Parkinson's disease patient in a phase 1 trial of its cell-based therapy DA01, which aims to replenish the neurons lost in people with ...

The sun found its way through the clouds as the first sod was cut for the advanced laboratory facility Cellerator, to be ...

Parkinson's disease (PD) is the second most common neurodegenerative ... nature of the nigrostriatal lesion in PD, dopaminergic cell transplantation has emerged as a potentially reparative therapy ...

The final phase of a clinical trial aiming to treat familial Alzheimer's disease using existing medication for Parkinson's ...